Signal Genetics Inc Stock Nasdaq
Stocks
US8266401046
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 09-16 | Sling Therapeutics raises $123 million to advance thyroid eye disease drug | RE |
| 08-31 | Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push | RE |
| Market Cap | 2.15B 1.91B 1.79B 1.63B 3.07B 207B 3.11B 21.62B 8.37B 105B 8.08B 7.9B 339B | P/E 2026 * |
-4.8x | P/E 2027 * | -7.41x |
|---|---|---|---|---|---|
| Enterprise Value | 1.36B 1.21B 1.13B 1.03B 1.94B 131B 1.97B 13.71B 5.31B 66.9B 5.12B 5.01B 215B | EV / Sales 2026 * |
45.4x | EV / Sales 2027 * | 7.05x |
| Free-Float |
99.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Signal Genetics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 55 | 2023-10-29 |
Seth Harmon
DFI | Director of Finance/CFO | 46 | 2023-09-11 |
Kirk Bertelsen
CTO | Chief Tech/Sci/R&D Officer | - | 2023-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 74 | 2018-01-02 |
Tomas Kiselak
CHM | Chairman | 40 | 2021-05-31 |
Jennifer Moses
BRD | Director/Board Member | 51 | 2021-07-13 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | +3.04% | +49.37% | +94.17% | 74.41B | |
| -1.16% | -1.59% | +24.37% | +78.12% | 59.26B | |
| +0.75% | -0.53% | +4.39% | +34.65% | 47.14B | |
| -3.02% | -5.20% | +27.94% | +32.51% | 42.91B | |
| +0.31% | +3.02% | +348.95% | +643.82% | 44.13B | |
| -1.96% | -0.33% | +7.04% | +99.46% | 40.79B | |
| +3.32% | +3.49% | +10.10% | +51.23% | 30.77B | |
| -2.68% | +2.92% | +29.63% | +22.72% | 29.31B | |
| -4.86% | -10.66% | -26.27% | +330.06% | 23.71B | |
| Average | -0.57% | -0.52% | +52.84% | +154.08% | 43.6B | |
| Weighted average by Cap. | -0.03% | -0.32% | +58.01% | +145.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.04M 26.69M 24.96M 22.74M 42.81M 2.89B 43.4M 302M 117M 1.47B 113M 110M 4.73B | 234M 208M 194M 177M 333M 22.53B 338M 2.35B 910M 11.47B 878M 859M 36.85B |
| Net income | -464M -412M -385M -351M -661M -44.68B -670M -4.66B -1.81B -22.76B -1.74B -1.7B -73.09B | -320M -284M -266M -242M -456M -30.78B -462M -3.21B -1.24B -15.68B -1.2B -1.17B -50.35B |
| Net Debt | -787M -699M -654M -596M -1.12B -75.78B -1.14B -7.91B -3.06B -38.59B -2.96B -2.89B -124B | -501M -445M -416M -379M -714M -48.26B -724M -5.04B -1.95B -24.58B -1.88B -1.84B -78.94B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
